We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
News

Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
News

Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda Cambridge.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: “We are proud to be selected by Takeda Cambridge to collaborate on this important project.  We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partner’s drug discovery efforts. We look forward to working with Takeda Cambridge.”

Dr Andrew Ayscough, Director of Chemistry at Takeda Cambridge, commented: “We are pleased to have this opportunity to work with Evotec making use of their hit identification platform.”

No financial details are disclosed.

Advertisement